Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. - Wikidata - wikimedia - TriplyDB

Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome.

Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome.

http://www.wikidata.org/entity/Q35849691

about

Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11 Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay The Biology of Annexin A2: From Vascular Fibrinolysis to Innate Immunity Mesangial cell-specific antibodies are central to the pathogenesis of lupus nephritis Cardiac xenotransplantation: progress and challenges A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies.Antiphospholipid antibodies: paradigm in transition.Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule.Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.Impaired fibrinolysis in the antiphospholipid syndrome.Plasminogen promotes macrophage phagocytosis in mice Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy.Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis.Feedback regulation of endothelial cell surface plasmin generation by PKC-dependent phosphorylation of annexin A2.The annexin A2 system and vascular homeostasis Annexin A2 as a target endothelial cell membrane autoantigen in Behçet's disease Fibrinolysis and the control of blood coagulation.Hypoxia-inducible factor-1 drives annexin A2 system-mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice."New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome Pathophysiology of the antiphospholipid antibody syndrome.The Annexin a2 Promotes Development in Arthritis through Neovascularization by Amplification Hedgehog Pathway Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies Antiphospholipid Antibodies in Lupus Nephritis.The annexin A2/S100A10 system in health and disease: emerging paradigms Annexin A2 Enhances Complement Activation by Inhibiting Factor H Pathophysiological mechanisms in antiphospholipid syndrome Annexin A2 heterotetramer: structure and function Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases.Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome.Some antiphospholipid antibodies bind to hemostasis and fibrinolysis proteases and promote thrombosis.Annexin A2: biology and relevance to the antiphospholipid syndrome.Annexin A2 system in human biology: cell surface and beyond.Proteomics in antiphospholipid syndrome: a review.Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment.Plasminogen receptors and their role in the pathogenesis of inflammatory, autoimmune and malignant disease.Toll-like receptors play a crucial part in the pathophysiological activity of antiphospholipid antibodies.Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.The antiphospholipid syndrome: from pathophysiology to treatment.

P2860

Q24647711-8A64B890-95E2-49CE-A345-C5AA1E8A4445 Q26739950-720CE439-8718-4416-8713-453FA114F3A3 Q26795375-2EAE2F59-929D-47D1-8B6C-3D07349F2D11 Q26991887-0046E4C5-F1B3-4F14-ADD5-46CFD288A5A7 Q27024045-4BBEC3C7-224B-42D5-A2C2-D855AB74F22A Q30422807-0D2F2E95-B7C1-4E1E-8491-52D5AA2C9377 Q33382848-28C3C4A7-A046-4AAF-A5DD-7948E83BA182 Q33741075-C8840E03-F343-4A5A-B90A-04EA1262B8DC Q33766670-1BDFFF5B-0400-4BB4-83C0-DFC13923A0AB Q33822542-418A43C0-D9D1-4253-8706-8BF6B740A902 Q33987072-C010C3E2-9A4D-4551-B18B-E122EFE00547 Q34080920-0A48624E-BDB1-4DD8-8EA8-EB2B4499C477 Q34245642-6ED0950D-27A4-464E-AD06-58074B026D2B Q34312466-6E6D1E87-7613-4A3C-B2E3-F006F8C4CECB Q34787911-D93711BE-B987-45C4-BE02-DC550C05D005 Q34869404-6A8679C5-0D77-40C2-AAE9-0E1F5592E795 Q35028300-6C251E6C-1116-4EB5-9916-0EB1E982D911 Q35035563-883F0CE2-DC0B-4848-A944-113E6DEC2F7B Q35039847-9BC0CCE3-1D52-49C6-9F57-6A5204DFE479 Q35212416-ADE6E4FC-5B31-44E0-A0E9-7978D94D4CD5 Q35250419-09972B5B-3CBC-4438-8EB0-6BEC16637D8E Q35309024-31C6F719-CA95-4CE9-9E2C-29DBE7DB7A4A Q35952353-3EA626AC-A6E3-485B-97DA-9AB340083E63 Q36013878-10D777B3-4F02-4FA5-8600-8B2D9C412988 Q36060060-AC864791-7442-4CA7-8CEE-475E60C1E342 Q36395285-DC2E9542-1F1B-4B58-875F-F57E1D883BA6 Q36495141-F376BC26-9388-4DA8-9DD1-9176E9799F04 Q36671159-9961D13B-7F3B-4911-AB6D-956E285829B6 Q36790362-A2AE5ABB-3D93-4990-98B2-234A33ED0531 Q37270868-01C857DD-6E25-4050-B1A3-82F4DDD8B7F5 Q37283006-311038BC-0CDB-418F-AABF-D709C56545B6 Q37283026-5A84F7C4-6520-4423-84D7-7FFBA7E006BC Q37283042-CF42906A-B55A-4CD0-92DA-37D98ABAC47E Q37406212-DD4D6A8D-A81D-42F3-A649-DC0D6DEDC351 Q37721600-2C0BA612-B661-4F8E-B553-20AE3ABEF223 Q37842673-D98FC871-BCAF-4B65-805B-7CCB150B8469 Q38058828-BBD631EB-BCC9-4855-8F69-CB6D59CFD9D2 Q38497394-C6D21A1E-61FE-4295-85DC-9B3B4CC338F1 Q38657043-3B6E3786-E4F9-4F7E-A922-A2FF802072D1 Q38873953-66BE5723-5133-47C0-AFDB-12DD9EBC3A33

P2860

Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome.

http://www.wikidata.org/entity/Q35849691

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Autoantibodies against the fib ...... in antiphospholipid syndrome.

@ast

Autoantibodies against the fib ...... in antiphospholipid syndrome.

@en

type

label

Autoantibodies against the fib ...... in antiphospholipid syndrome.

@ast

Autoantibodies against the fib ...... in antiphospholipid syndrome.

@en

prefLabel

Autoantibodies against the fib ...... in antiphospholipid syndrome.

@ast

Autoantibodies against the fib ...... in antiphospholipid syndrome.

@en

P1433

Q35849691-0C4924CC-6948-4651-8373-40C5CA4DFB0A

P1476

Q35849691-9DCAF4D7-7F12-4F46-8F3A-A570BD0898AC

P2093

Q35849691-1949C6DD-BE83-4168-B740-0E7648451E0D

Q35849691-2FB46299-7968-4A0E-8A04-BE50DBE9E532

Q35849691-897D9A93-6633-4836-8BB1-BAC7AE340E56

Q35849691-A4A2D831-C2CF-47A4-B363-3BF55F165ACA

Q35849691-D1B8199B-5AFD-48E4-9D52-ABB542419686

Q35849691-EB245253-EE54-484A-9C17-ECA0CCA4235C

Q35849691-EE69A55A-4C44-4304-9312-8AAC4DE44030

P2860

Q35849691-041D71BD-5BFF-4D4F-9544-17136375355E

Q35849691-1D71A5B3-B316-4695-9F9F-318258F47A26

Q35849691-2730FD1D-5B9A-412A-8A49-011A14E5FC3D

Q35849691-2C28E88C-7318-4F29-B3EF-936AD14DFE00

Q35849691-2C2E178A-3BC4-4C9D-BECE-5FF27565E8B9

Q35849691-2F53844E-8AA9-41C8-B714-0CA9E8026B4E

Q35849691-2FEA549B-6FBA-47A2-B291-A23492A2DE17

Q35849691-327E163C-B8D7-4E77-9889-5DD5631014BD

Q35849691-361A0CFD-32A0-4BAB-A9C5-3423BCBDFB4D

Q35849691-37367131-FB00-4C9D-AB93-610E4D116799

P304

Q35849691-133A824A-F871-4689-8F80-0E57E33C6503

P31

Q35849691-E13F3BAE-95C2-4AD9-A380-F62A26DE3EC9

P356

Q35849691-66A3F876-1EEC-4E2E-A864-A12DD4CBF18B

P407

Q35849691-567E2C31-ECAF-4423-917E-3FDBB8D88768

P433

Q35849691-D122EDCB-A186-4B66-BE9C-12766B5F8B11

P478

Q35849691-7A45E0C8-E6D1-4C8B-9701-00D14829289F

P50

Q35849691-08D71657-15B5-42C3-AB5B-46EAB21ABA69

Q35849691-AB222F90-28F8-4670-AEB7-71B573B9C3B1

P577

Q35849691-00F78BD5-27E1-40BC-ABD3-E39A73C8C887

P5875

Q35849691-71EE85ED-7475-46F1-B528-575F8362F04B

P698

Q35849691-5B7CA247-E9C0-4789-BE0C-F38F82E7F49A

P921

Q35849691-79748B27-653E-4FC1-AE86-D2F57F3619C0

P932

Q35849691-B096F819-6812-4347-96A1-59477C4BFEB4

P356

BLOOD-2005-07-2636

P1433

P1476

Autoantibodies against the fib ...... in antiphospholipid syndrome.

@en

P2093

Arunkumar B Deora

http://www.w3.org/2001/XMLSchema#string

Donato Alarcón-Segovia

http://www.w3.org/2001/XMLSchema#string

Jorge Sánchez-Guerrero

http://www.w3.org/2001/XMLSchema#string

Katherine A Hajjar

http://www.w3.org/2001/XMLSchema#string

Maria del Carmen Cravioto

http://www.w3.org/2001/XMLSchema#string

Nina P Ríos-Luna

http://www.w3.org/2001/XMLSchema#string

Rosario Villa

http://www.w3.org/2001/XMLSchema#string

P2860

High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)

Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia

Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo

Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies

Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor

Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery

Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome.

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

Unusual manifestations of the antiphospholipid syndrome.

P304

4375-4382

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-07-2636

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Gabriela Cesarman-Maus

P577

2006-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7284278

http://www.w3.org/2001/XMLSchema#string

P698

16493010

http://www.w3.org/2001/XMLSchema#string

P921

P932

1895790

http://www.w3.org/2001/XMLSchema#string